SCHEMBL1480663

SCHEMBL1480663

COc1ccccc1-c1ccc(C=Cc2nc(-c3ccc(Cl)cc3Cl)c[nH]2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.41
DPP4 P27487 2/20 0.40
XDH P47989 1/20 0.40
DPP8 Q6V1X1 1/20 0.38
CRHR1 P34998 1/20 0.38
MARS1 P56192 2/20 0.38
ACHE P22303 1/20 0.38
BACE1 P56817 1/20 0.38
KDM4E B2RXH2 4/20 0.37
MAPT P10636 2/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
HPGD P15428 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
HCRTR1 O43613 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37
MAPK1 P28482 1/20 0.37
CASP3 P42574 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1480659 1.00 PDGFRB (0.41) PDGFRBDPP4XDHDPP8CRHR1
SCHEMBL1481657 0.92 AGPAT2 (0.39) PDGFRBCRHR1ACHEBACE1KDM4E
SCHEMBL1481654 0.92 AGPAT2 (0.39) PDGFRBCRHR1ACHEBACE1KDM4E
SCHEMBL1481153 0.89 MEN1 (0.40) DPP4ACHEBACE1KDM4EMAPT
SCHEMBL1481149 0.89 MEN1 (0.40) DPP4ACHEBACE1KDM4EMAPT
SCHEMBL1483102 0.87 KIT (0.41) PDGFRBACHEBACE1KDM4EMAPT
SCHEMBL1483101 0.87 KIT (0.41) PDGFRBACHEBACE1KDM4EMAPT
SCHEMBL1481070 0.85 MAPT (0.44) DPP4DPP8MARS1KDM4EMAPT
SCHEMBL1481066 0.85 MAPT (0.44) DPP4DPP8MARS1KDM4EMAPT
SCHEMBL1480766 0.85 PTGES (0.44) DPP4BACE1KDM4EMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
EP-1594847-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS Transtech Pharma, Inc. (US) 2005-11-16 EP disclosed
WO-2004071447-A9 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC (US) 2005-10-13 WO disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed
WO-2004071447-A2 SUBSTITUTED AZOLE DERIVATIVES AS THERAPEUTIC AGENTS TRANSTECH PHARMA INC. (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ PDGFRB 2252/4885DPP4 132/4885XDH 127/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ PDGFRB 2252/4885DPP4 132/4885XDH 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.